Elizabeth Grammer, Esq., is a distinguished legal executive with more than 25 years of experience in the biotechnology and pharmaceutical sectors. A graduate of the University of California, Hastings College of the Law, she began her career at a leading Silicon Valley law firm, where she specialized in corporate transactions, securities law, and regulatory compliance for life sciences companies. Grammer's early roles included general counsel positions at several emerging biotech firms, honing her expertise in FDA regulatory affairs, intellectual property strategy, and mergers and acquisitions, which established her as a trusted advisor in high-stakes industry environments. As Former Chief Legal and Administrative Officer at Ardelyx Inc., a biopharmaceutical company focused on innovative therapies for gastrointestinal and cardiorenal diseases, Grammer led the company's legal, compliance, risk management, and administrative operations from 2014 to 2022. She played a pivotal role in Ardelyx's successful NASDAQ initial public offering in 2016, raising over $100 million, and guided the company through multiple FDA approvals, including the landmark launch of IBSRELA (tenapanor) for irritable bowel syndrome with constipation in 2022. Her strategic oversight ensured robust intellectual property protection, facilitated key strategic partnerships, and navigated complex clinical and commercial milestones, significantly contributing to Ardelyx's growth into a commercial-stage enterprise. Grammer's achievements at Ardelyx were complemented by her leadership in fostering a culture of ethical compliance and operational excellence, earning her recognition from industry peers. Post-Ardelyx, she remains active as a board advisor and consultant to biotech ventures, leveraging her deep industry knowledge to support innovation and sustainable growth.